enosix, Inc. Closes $10 Million Financing with MK Capital to Support Real-Time SAP Integration
16.5.2023 16:00:00 EEST | Business Wire | Press release
enosix, Inc., the leading technology provider of real-time, prebuilt SAP data integration solutions, announced the successful completion of its $10 million growth financing led by MK Capital. enosix will use the proceeds to accelerate the development and expansion of its SAP integration platform, while expanding its support of Salesforce, MuleSoft, and ServiceNow clients.
enosix is the proven, SAP data integration approach that is relied upon by leading global manufacturers including recent customer additions, Prevost, a member of Volvo Group, Tremco Inc., and Carl Zeiss AG. enosix empowers SAP ERP customers with the critical last mile of integration in real-time, boosting digital transformation efforts by eliminating error-prone, latent, swivel-chair data entry between systems. enosix uplevels data accuracy, automation and business agility in areas such as, but not limited to, sales quoting, IT asset management, business supply-chain management, B2B eCommerce, and more, allowing for greater utilization of business and SAP skilled resources. These advantages translate to a superior customer experience and greater revenue growth.
“Over the past 30 years we have performed detailed due diligence on hundreds of technology companies,” noted Mark Koulogeorge of MK Capital.“ We have never had a company score higher on product quality and reliability than enosix. The product’s high performance over millions of transactions differentiates enosix from its competitors.”
Jamie Bedard, CEO of SAPinsider observed,“The enterprise landscape for SAP customers continues to become more complex. The accelerated adoption of cloud-based solutions as a result of the global pandemic has only added to this complexity. enosix’s unique approach to real-time, virtualized SAP integration triggers a huge sigh of relief by the SAP industry and offers a potential safety net for tens of thousands of enterprise SAP ERP customers who are not only behind in their S/4HANA migration projects, but those who are trying to keep up with the business demands of digital transformation but don’t have the time, resources, or skilled SAP talent available to support a major traditional integration project.”
Nick Fera, CEO of enosix noted “The increasing demand for pre-built, real-time, bi-directional access to legacy ERP solutions, especially during these difficult economic times, positions enosix for tremendous growth. Companies are tired of paying millions to systems integrators for bespoke integration solutions that offer only synchronous experience and require long-term maintenance. The ability to ‘have a two-way conversation’ with your legacy ERP solutions is no longer a dream, enosix has delivered a platform to handle complex pricing and quoting and is now better positioned to expand.”
About enosix, Inc
enosix is the standard for real-time, prebuilt SAP ERP integration. enosix provides real-time data virtualization, which enables a more agile and compliant customer experience by reducing error-prone data entry and information delays. enosix seamlessly connects SAP ECC and S/4HANA systems to modern front-end systems such as Saleforce, MuleSoft, ServiceNow to support rapid digital transformation. The enosix platform leverages low or no-code Packaged Integration Processes (PIP) so companies can quickly realize value—in weeks instead of months. enosix' use of data virtualization unlocks data, business processes, authorizations, and user permissions from SAP without recreating them from the front-end; delivering the back-end translation in an easy-to-understand, real-time, and bi-directional integration. For more information, visit www.enosix.com
About MK Capital
MK Capital is an early-stage lead investor in the software and cloud services industries. The firm's partners, who average more than 20 years of venture capital experience, actively partner with entrepreneurial management teams to build leading companies that accelerate the digital transformation of the global economy. MK Capital manages over $400 million in capital and is actively seeking new investment opportunities. For more information, visit www.mkcapital.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005351/en/
Contact information
Loren Shumate
EMAIL: Loren.Shumate@enosix.com
Follow enosix:
https://enosix.com
https://www.linkedin.com/company/enosix/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom